The European Union’s proposed Critical Medicines Act (CMA) is the clearest signal yet that pharmaceutical supply chains are entering a new era in which resilience — not cost alone — is becoming the benchmark for performance.
The COVID-19 pandemic, geopolitical instability, growing demand for essential medicines, and ongoing raw material shortages have exposed how vulnerable globalised networks are.
In Europe, medicine shortages are no longer isolated incidents, but a persistent challenge affecting everything from antibiotics to oncology treatments.
These are structural weaknesses that can no longer be ignored, writes Helen Yeman (pictured), Marketing Director, Pharma, at dsm-firmenich Health, Nutrition and Care.
Not yet a Subscriber?
This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Manufacturing Chemist.
Subscribe now Already a subscriber? Sign in here.
